Updated on 15 May 2013
Japan's Menicon opened its first R&D and manufacturing facility outside Japan in Singapore, with total investments of $99 million and developed the world's thinnest one-day disposable contact lens utilizing flat pack technology. Recognizing the opportunities in Singapore, US-based Greatbatch established its R&D center for active implantable medical devices in Asia. Its QiG Singapore R&D Center focusses on the design and development of active implantable medical devices to serve the cardiovascular and neuromodulation markets. Becton Dickinson has expanded its corporate R&D center in Singapore to develop healthcare solutions in the area of medical surgical, immunization and diagnostics for Asian markets.
With its focus on quality and high standards, medical technologies developed at Singapore have managed to get green flag from US FDA as well. Quattro Vascular, a subsidiary of TriReme Medical, received FDA approval for their medical device, Chocolate percutaneous transluminal angioplasty (PTA) balloon catheter. This is the first implantable device developed in Singapore, to be approved by the FDA. The product was developed in Singapore by a 10-person R&D team.
In a bid to strengthen its medtech base, EDB has launched IDEAS (Innovate, Design, Engineer for Asia in Singapore) program for helping the medtech sector to train multidisciplinary teams of engineers, specialists and regulatory experts in companies' global and Singapore-based R&D facilities. The country has also created the Singapore-Stanford Biodesign Program, which is designed to meet the medtech industry's need for Asian medical device innovators, who are familiar with medtech innovation process as well as Asia's healthcare needs.